Should we administer sildenafil to patients with obstructive pulmonary disease and pulmonary hypertension? No.
Silvio A
SA
Namendys-Silva
Marisol
M
Hernández-Garay
D015897:Comorbidity; D004305:Dose-Response Relationship, Drug; D005080:Exercise Test; D017079:Exercise Tolerance; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000145:classification / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D011687:Purines / Q000008:administration & dosage / Q000627:therapeutic use; D012720:Severity of Illness Index; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000008:administration & dosage / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate